Advertisement

Topics

GeNeuro SA Company Profile

00:00 EDT 20th June 2018 | BioPortfolio


News Articles [13 Associated News Articles listed on BioPortfolio]

GeNeuro: Annual Report on the Liquidity Contract with Gilbert Dupont

Market: Euronext ParisISIN code Mnemo: CH0308403085 GNROWeb site: www.geneuro.com Regulatory News: Pursuant to the liquidity contract entrusted by GENEURO SA (Paris:GNRO) to Gilbert Dupont, as of ...

FDA orphan status given to Geneuro's CIDP therapy

Geneuro's GNBAC1 was given orphan drug status by the FDA as a treatment for patients with chronic inflammatory demyelinating  -More- 

GeNeuro Publishes the English Version of Its 2017 Registration Document

Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO) (Paris: GNRO), a biopharmaceutical company developing new treatments for autoimmune diseases, including multiple sclerosis and Type 1 d...

Positive Phase IIb results under GeNeuro and Servier MS collaboration

GeNeuro and French independent pharma company Servier today announced positive results at 12 months from…

This Multiple Sclerosis Drug Could Help to Fight Another Autoimmune Disease

The FDA has awarded Orphan Drug Designation to GeNeuro’s antibody for the treatment of a rare autoimmune disease following promising Phase IIb results in multiple sclerosis patients. GeNeuro dev...

Attacking an Ancient Virus Slows Multiple Sclerosis in Phase II

GeNeuro has released Phase IIb data showing that its antibody can reduce brain damage in patients with multiple sclerosis by going after an unusual target: a virus that has been in our genome since an...

GeNeuro reports 12-month Phase IIb data for RRMS candidate

GeNeuro Receives Orphan Drug Designation from the US FDA for GNbAC1 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

GNbAC1 targets pHERV-W env, which is found in half of CIDP patients Forthcoming discussions expected with the FDA for the design of a proof-of-concept Phase 2 clinical study Regulatory News: GeNeu...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

GeNeuro

GeNeuro is a Swiss-based company created by Eclosion in 2006 as a spin-off of bioMérieux and co-funded by Eclosion and the Institut Mérieux. GeNeuro is developing first-in-c...

GeNeuro SA

More Information about "GeNeuro SA" on BioPortfolio

We have published hundreds of GeNeuro SA news stories on BioPortfolio along with dozens of GeNeuro SA Clinical Trials and PubMed Articles about GeNeuro SA for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of GeNeuro SA Companies in our database. You can also find out about relevant GeNeuro SA Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record